Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
| 432 | 3 | TRAIL//SURVIVIN//APOPTOSIS | 28744 |
| 258 | 2 | TRAIL//SURVIVIN//APOPTOSIS | 19509 |
| 24946 | 1 | OBLIMERSEN//CT120//GROWTH FACTOR DEPRIVATION THERAPY | 319 |
Terms with highest relevance score |
| rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|---|
| 1 | OBLIMERSEN | authKW | 592777 | 4% | 50% | 12 |
| 2 | CT120 | authKW | 395193 | 1% | 100% | 4 |
| 3 | GROWTH FACTOR DEPRIVATION THERAPY | authKW | 296395 | 1% | 100% | 3 |
| 4 | G3139 | authKW | 296383 | 3% | 33% | 9 |
| 5 | ANTISENSE BCL 2 | authKW | 222295 | 1% | 75% | 3 |
| 6 | EXPT ONCOL MOL PHARMACOL | address | 197596 | 1% | 100% | 2 |
| 7 | GENASENSE | authKW | 197596 | 1% | 100% | 2 |
| 8 | ALBERT E EIN MONTEFIORE CANC | address | 143701 | 1% | 36% | 4 |
| 9 | ANGIOIMMUNOBLASTIC T CELL LYPHOMA | authKW | 98798 | 0% | 100% | 1 |
| 10 | ANTI BCL 2 THERAPY | authKW | 98798 | 0% | 100% | 1 |
Web of Science journal categories |
| chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | Oncology | 3345 | 53% | 0% | 169 |
| 2 | Medicine, Research & Experimental | 304 | 13% | 0% | 40 |
| 3 | Urology & Nephrology | 146 | 7% | 0% | 22 |
| 4 | Cell Biology | 87 | 10% | 0% | 33 |
| 5 | Biochemistry & Molecular Biology | 37 | 13% | 0% | 43 |
| 6 | Hematology | 24 | 3% | 0% | 11 |
| 7 | Pharmacology & Pharmacy | 19 | 7% | 0% | 23 |
| 8 | Biotechnology & Applied Microbiology | 14 | 4% | 0% | 14 |
| 9 | Anatomy & Morphology | 10 | 1% | 0% | 3 |
| 10 | Genetics & Heredity | 7 | 3% | 0% | 11 |
Address terms |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | EXPT ONCOL MOL PHARMACOL | 197596 | 1% | 100% | 2 |
| 2 | ALBERT E EIN MONTEFIORE CANC | 143701 | 1% | 36% | 4 |
| 3 | BIOCHEM SCI A ROSSI FANIELLI | 98798 | 0% | 100% | 1 |
| 4 | BONE MARROW TRANSPLANTAT CHILDREN ONCOL HA | 98798 | 0% | 100% | 1 |
| 5 | EXPT CHEMOTHERPAY | 98798 | 0% | 100% | 1 |
| 6 | INTERDISCIPLINARITY PALLIAT CARE NURSING | 98798 | 0% | 100% | 1 |
| 7 | MOL ONKOIMMUNOL | 98798 | 0% | 100% | 1 |
| 8 | NCI COMPRREHENS CANC | 98798 | 0% | 100% | 1 |
| 9 | NEW YORK CANC CONSORTIUM COORDINATING | 98798 | 0% | 100% | 1 |
| 10 | PATHOL EXPT CANCEROGENESIS | 98798 | 0% | 100% | 1 |
Journals |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | MEDICAL ONCOLOGY | 6516 | 5% | 0% | 15 |
| 2 | CLINICAL CANCER RESEARCH | 3705 | 8% | 0% | 24 |
| 3 | OLIGONUCLEOTIDES | 3300 | 1% | 1% | 3 |
| 4 | IN VIVO | 2365 | 3% | 0% | 8 |
| 5 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 1058 | 1% | 1% | 2 |
| 6 | MOLECULAR CANCER THERAPEUTICS | 837 | 2% | 0% | 6 |
| 7 | CLINICAL LYMPHOMA | 724 | 0% | 1% | 1 |
| 8 | CURRENT OPINION IN ONCOLOGY | 614 | 1% | 0% | 3 |
| 9 | METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 600 | 1% | 0% | 4 |
| 10 | MOLECULAR UROLOGY | 563 | 0% | 1% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |